<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130260</url>
  </required_header>
  <id_info>
    <org_study_id>Nabi-1372</org_study_id>
    <nct_id>NCT00130260</nct_id>
  </id_info>
  <brief_title>Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease</brief_title>
  <acronym>SHIELD-2</acronym>
  <official_title>Phase 3b Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating Immunogenicity and Safety of a 3rd and 4th Dose of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults With End-Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nabi Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus
      aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease
      patients, by giving a 3rd and 4th dose to a subset of the participants in the previous
      efficacy trial. Participants continue to receive the vaccine or placebo in a blinded manner,
      and are also randomly assigned to 1 of 2 different intervals between the doses. The
      immunogenicity is measured by the antibodies in the blood, and typical vaccine safety
      information is also collected.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unsatisfactory efficacy data from preceding trial
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serotype-specific antibody concentrations</measure>
    <time_frame>6 weeks after each dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serotype-specific antibody concentrations</measure>
    <time_frame>at several other time points up to 12 months after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>elicited vaccine reactogenicity</measure>
    <time_frame>daily for 7 days after each dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Staphylococcal Infections</condition>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>vaccine, schedule 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3rd and 4th dose of vaccine, on original schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine, schedule 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3rd and 4th dose of vaccine on modified schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, schedule 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3rd and 4th dose of placebo, on original schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, schedule 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3rd and 4th dose of placebo on modified schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Staph aureus types 5 and 8 conjugate vaccine</intervention_name>
    <description>each IM dose contains 200 mc total conjugate</description>
    <arm_group_label>vaccine, schedule 1</arm_group_label>
    <arm_group_label>vaccine, schedule 2</arm_group_label>
    <other_name>StaphVAX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo to match StaphVAX</description>
    <arm_group_label>placebo, schedule 1</arm_group_label>
    <arm_group_label>placebo, schedule 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in prior study Nabi-1371

          -  Written informed consent

          -  Negative serum pregnancy test, where appropriate

          -  Expect to comply with protocol procedures and schedule

        Exclusion Criteria:

          -  Known HIV

          -  Immunomodulatory drugs

          -  Malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the
             cervix, or early stage prostate cancer)

          -  Active infection in the 2 weeks prior to study injection

          -  Serious S. aureus infection within the last 2 months prior to injection

          -  Hypersensitivity to components of StaphVAX
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Hohenboken, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nabi Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>multiple sites: contact Central Study coordination</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <last_update_submitted>December 26, 2007</last_update_submitted>
  <last_update_submitted_qc>December 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matt Hohenboken, MD, PhD, Executive Director Clinical &amp; Medical Affairs</name_title>
    <organization>Nabi Biopharmaceuticals</organization>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

